Cocrystal Pharma, Inc. (COCP) NASDAQ
1.43
+0.04(+2.88%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.43
+0.04(+2.88%)
Currency In USD
| Previous Close | 1.39 |
| Open | 1.4 |
| Day High | 1.46 |
| Day Low | 1.4 |
| 52-Week High | 2.67 |
| 52-Week Low | 0.86 |
| Volume | 135,913 |
| Average Volume | 2.43M |
| Market Cap | 14.66M |
| PE | -1.83 |
| EPS | -0.78 |
| Moving Average 50 Days | 1.2 |
| Moving Average 200 Days | 1.22 |
| Change | 0.04 |
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or vaccines are available for norov
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
GlobeNewswire Inc.
Feb 19, 2026 1:00 PM GMT
CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis caused by norovirus infectionThere are no ap